Safety of everolimus plus exemestane in patients with hormone-receptor–positive, HER2–negative locally advanced or metastatic breast cancer progressing on prior non-steroidal aromatase inhibitors: primary results of a phase IIIb, open-label, single-arm, expanded-access multicenter trial (BALLET)
| Autor: | Jerusalem, G. *, Mariani, G., Ciruelos, E.M., Martin, M., Tjan-Heijnen, V.C.G., Neven, P., Gavila, J.G., Michelotti, A., Montemurro, F., Generali, D., Simoncini, E., Lang, I., Mardiak, J., Naume, B., Camozzi, M., Lorizzo, K., Bianchetti, S., Conte, P. |
|---|---|
| Zdroj: | In Annals of Oncology September 2016 27(9):1719-1725 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|